March 2017, Vol 7, No 3

National Cancer Mortality Rates Decline, but Some Regions See an Increase

By Laura Morgan

Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?

By Phoebe Starr

Emerging Therapies

Anti-CD19 CAR T-Cell Therapy After Stem-Cell Transplantation Effective in Advanced Multiple Myeloma

By Wayne Kuznar

Emerging Therapies, Multiple Myeloma

CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia

By Wayne Kuznar

Emerging Therapies

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

By Wayne Kuznar

GI Cancers Symposium

Concurrent EGFR and BRAF Inhibition Improves PFS in BRAF V600 Mutation–Positive Colorectal Cancer

By Wayne Kuznar

GI Cancers Symposium

Nivolumab a New Treatment Option for Patients with Advanced Gastric Cancer

By Wayne Kuznar

GI Cancers Symposium

Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

Medications Used for the Treatment of Multiple Myeloma and Associated ICD-10 Codes

By Kristin A. Esposito, CPhT

Cancer Drug Coding, ICD Codes, Reimbursement

This detailed article of codes related to multiple myeloma is intended to assist practice managers and other healthcare providers and payers to ensure the proper use of coding and billing information associated with the treatment of patients with multiple myeloma. Read More ›

Adding Antiandrogen Therapy to Radiation Improves Survival in Recurrent Prostate Cancer—A New Standard of Care?

By Jessica Miller

Prostate Cancer

Page 1 of 2

1
2